Biomarker Core

生物标志物核心

• 批准号: 10663884
• 负责人: ALICE S CHEN-PLOTKIN
• 金额: $ 24.57万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10663884
• 关键词: Aging; Alzheimer' s Disease; Alzheimer' s disease related dementia; Alzheimer’s disease biomarker; Amyloid; Amyloid beta-Protein; Area; Autopsy; Biochemical; Biological Assay; Biological Markers; Blood; Blood Vessels; Blood specimen; Cessation of life; Cholesterol; Classification; Classification Scheme; Clinical; Collaborations; Collection; Communities; Consultations; Data; Dementia; Development; Doctor of Philosophy; Fostering; Genomics; Glycosylated hemoglobin A; Goals; Homocysteine; Image; Individual; Interleukin-6; Investigation; Ligands; Light; Literature; Magnetic Resonance Imaging; Measures; Molecular; Molecular Diagnosis; National Institute on Alcohol Abuse and Alcoholism; Nerve Degeneration; Normal Range; Participant; Pathology; Pennsylvania; Plasma; Positron-Emission Tomography; Process; Protocols documentation; Reporting; Research; Research Personnel; Risk; Sampling; Scheme; Site; Testing; Training; Translational Research; Universities; Vascular Diseases; Visit; assay development; biomarker validation; clinical heterogeneity; clinical phenotype; disorder risk; education research; feasibility testing; imaging biomarker; neurofilament; neuroimaging; neuropathology; peer; structural imaging; tau Proteins; tau-1; vascular contributions

BIOMARKER CORE SUMMARY: With the increasing emphasis in the Alzheimer’s Disease (AD) field on molecular diagnosis, the Biomarker Core has two over-arching goals. First, we will continue a highly-successful tradition at the University of Pennsylvania of banking and widely dispersing biofluid samples obtained by the Clinical Core, while annotating these samples with baseline molecular measures that allow for Amyloid-Tau-Neurodegeneration (A/T/(N)) classification within the NIA-AA framework. Second, we will pave new ground by relating well-established CSF- and imaging-based A/T/(N) biomarkers to measures obtained from emerging plasma-based biomarkers, and performing measures that will allow for investigation of the contribution of vascular disease to heterogeneity of clinical phenotype. These goals will be met through activities along five Specific Aims. AIM 1: Oversee and direct all banking and dispersal of biofluid samples obtained in ADRC UDS participants (current n=537). AIM 2: Characterize established biochemical biomarkers previously reported in the literature in order to annotate all Clinical Core samples within the A/T/(N) classification scheme. A CSF biochemical biomarker profile defined by (1) CSF amyloid-beta 1-42 (CSF Aβ42) and (2) 1-40 (CSF Aβ40), (3) CSF total tau (CSF t-tau), (4) CSF tau phosphorylated at residue 181 (CSF p-tau181), (5) CSF neurofilament light chain (CSF NfL), and (6) plasma NfL measures will be established. AIM 3: Relate emerging plasma-based biomarkers to established CSF and imaging biomarkers, as well as neuropathology. We will focus on assays of plasma p-tau and plasma Aβ, validating measures from samples obtained antemortem against postmortem findings. For well-validated assays, we will obtain plasma measures on all ADRC UDS participants. AIM 4: Collaborate with other Cores to investigate the contribution of vascular disease to heterogeneity of clinical phenotype. We will support the collection of biomarker measures (i.e. CRP, cholesterol, hemoglobin A1c, interleukin-6 (IL-6), homocysteine) that allow for assessment of vascular risk in all ADRC UDS participants. AIM 5: Provide advice and support to investigators within and outside the Penn ADRC.

生物标志物核心总结：